These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 9771090)
61. Efficacy of lodoxamide 0.1% ophthalmic solution in resolving corneal epitheliopathy associated with vernal keratoconjunctivitis. Santos CI; Huang AJ; Abelson MB; Foster CS; Friedlaender M; McCulley JP Am J Ophthalmol; 1994 Apr; 117(4):488-97. PubMed ID: 8154531 [TBL] [Abstract][Full Text] [Related]
62. Treatment of common ocular allergic disorders; a comparison of lodoxamide and NAAGA. Denis D; Bloch-Michel E; Verin P; Sebastiani A; Tazartes M; Helleboid L; Di Giovanni A; Lecorvec M Br J Ophthalmol; 1998 Oct; 82(10):1135-8. PubMed ID: 9924299 [TBL] [Abstract][Full Text] [Related]
63. Lodoxamide in vernal keratoconjunctivitis. Lee S; Allard TR Ann Pharmacother; 1996 May; 30(5):535-7. PubMed ID: 8740338 [TBL] [Abstract][Full Text] [Related]
64. Inhalation challenge with specific grass pollen antigens in asthmatics and the effect of lodoxamide tromethamine. Parrish RW; Davies BH Thorax; 1983 Jun; 38(6):458-62. PubMed ID: 6136101 [TBL] [Abstract][Full Text] [Related]
65. The current and future therapy of allergic conjunctivitis. Friedlaender MH Curr Opin Ophthalmol; 1998 Aug; 9(4):54-8. PubMed ID: 10387470 [TBL] [Abstract][Full Text] [Related]
73. The characterization of lodoxamide, a very active inhibitor of mediator release, in animal and human models of asthma. Johnson HG; Sheridan AQ Agents Actions; 1986 Jun; 18(3-4):301-5. PubMed ID: 2875630 [TBL] [Abstract][Full Text] [Related]
75. Antiallergic activity of topical lodoxamide on in vivo and in vitro models. Ciprandi G; Buscaglia S; Catrullo A; Paolieri F; Riccio AM; Fiorino N; Canonica GW Allergy; 1996 Dec; 51(12):946-51. PubMed ID: 9020426 [TBL] [Abstract][Full Text] [Related]
76. [Diagnosis and treatment of allergic conjunctivitis]. Saraux H; Blamoutier J Ann Ocul (Paris); 1967 Nov; 200(11):1189-92. PubMed ID: 4383941 [No Abstract] [Full Text] [Related]
77. Conjunctivitis of allergic origin: immunologic mechanisms and current approaches to therapy. Abelson MB; Schaefer K Surv Ophthalmol; 1993; 38 Suppl():115-32. PubMed ID: 7901917 [TBL] [Abstract][Full Text] [Related]
78. [GUIDELINES FOR THE CLINICAL MANAGEMENT OF ALLERGIC CONJUNCTIVAL DISEASE THE POINT OF THE MANAGEMENT WITH USING CONVENTIONAL TOOL AND EYE DROPS]. Takamura E Arerugi; 2018; 67(2):103-107. PubMed ID: 29553108 [No Abstract] [Full Text] [Related]
79. Treatment of adenoviral keratoconjunctivitis with a combination of povidone-iodine 1.0% and dexamethasone 0.1% drops: a clinical prospective controlled randomized study. Kovalyuk N; Kaiserman I; Mimouni M; Cohen O; Levartovsky S; Sherbany H; Mandelboim M Acta Ophthalmol; 2017 Dec; 95(8):e686-e692. PubMed ID: 28342227 [TBL] [Abstract][Full Text] [Related]
80. [Clinical evaluation of N-acetylaspartylglutamic acid eyedrops in subacute and chronic atopic conjunctivitis]. van Bijsterveld OP; Aalders-Deenstra V Klin Monbl Augenheilkd; 1986 Jun; 188(6):625-7. PubMed ID: 3093750 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]